Boston Scientific Corp (BSX)vsCytosorbents Crp (CTSO)
BSX
Boston Scientific Corp
$45.10
+4.83%
HEALTHCARE · Cap: $69.50B
CTSO
Cytosorbents Crp
$0.39
-5.94%
HEALTHCARE · Cap: $22.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 55314% more annual revenue ($20.61B vs $37.20M). BSX leads profitability with a 17.3% profit margin vs -31.9%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
CTSO
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-18.7%
Fair Value
$37.36
Current Price
$45.10
$7.74 premium
Intrinsic value data unavailable for CTSO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
No standout strengths identified
Areas to Watch
Distress zone — elevated risk
Trading at 9.8x book value
1.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : CTSO
CTSO has a balanced fundamental profile.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : CTSO
The primary concerns for CTSO are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 8.64 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a mature stock while CTSO is a turnaround play — different risk/reward profiles.
CTSO carries more volatility with a beta of 1.36 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 24/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Cytosorbents Crp
HEALTHCARE · MEDICAL DEVICES · USA
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?